The Semaglutide Cliff vs. a 10x Multiple: Is Novo Nordisk (NVO) a Value Trap or a Bargain?

Reported by Yahoo Finance · Published 21 Sep 2026, 7:23 AM MYT (1 hr ago)

Summary

Source & full coverage: this summary is aggregated from Yahoo Finance, the original publisher. Read the complete report for full context, data and quotes.

Read the original report at Yahoo Finance →

Most Recent

US Treasury chief says meeting with China on trade, AI ‘very successful’ 19 min ago New World Development bags Shanghai bourse nod for $570 million REIT listing 22 min ago Tech leads shares higher in Asia, oil eases 27 min ago Nvidia boss rejects AI extinction fears as 'doomsday narratives' 32 min ago Four Chinese firms seek to raise up to $1.83 billion in Hong Kong offerings 43 min ago Europe faces Q4 jet fuel supply deficit even as South Korea becomes latest big supplier 1 hr ago

EconPulse

Markets. Economy. Malaysia & The World.

Independent economic news aggregation for Malaysia, Asia and global markets, updated throughout the day.

Company

About Us Editorial Standards & Corrections Privacy Policy

Work With Us

Submit a Press Release Partnerships & Advertising Contact Us RSS Feed

Contact

editor@econpulse.my

Editorial & newsroom enquiries answered within 1–2 business days.

The Semaglutide Cliff vs. a 10x Multiple: Is Novo Nordisk (NVO) a Value Trap or a Bargain?

Summary

More in Markets

Analog Devices (ADI) Bets $1.35 Billion on Chips that Let Machines Think for Themselves

Still Working at 73? The IRS Lets You Skip RMDs on Your Current Employer’s 401(k) but Not on the IRA You Rolled Your Last One Into

Casey’s (CASY) Beats on Profit, but a Soft Sales Number Sends the Stock Tumbling

Prediction: Nvidia's Revenue Growth Will Drive Shares to $400 Next Year

A West Texas Ranch Got $1.3 Million for Water Rights. For a Medicare-Age Landowner, the Premium Bill Can Arrive Two Years Later

Signet Jewelers (SIG) Swings to a Profit and Signs a Credit Deal Worth $1 Billion